Novel therapeutic options in Acute Myeloid Leukemia

Publication date: Available online 1 October 2016 Source:Leukemia Research Reports Author(s): Michael Medinger, Claudia Lengerke, Jakob Passweg Acute myeloid leukemia (AML) is a biologically complex and molecularly and clinically heterogeneous disease, and its incidence is increasing as the population ages. Cytogenetic anomalies and mutation testing remain important prognostic tools for tailoring treatment after induction therapy. Despite major advances in understanding the genetic landscape of AML and its impact on the pathophysiology and biology of the disease, as well as the rapid development of new drugs, standard treatment options have not experienced major changes during the past three decades. Especially for patients with intermediate or high-risk AML, which often show relapse… Allogeneic hematopoietic stem cell transplantation (HSCT) remains the best chance for cure.. Here we review the state of the art therapy of AML, with special focus on new developments in immunotherapies and cellular therapies including HSCT and particularly discuss the impact of new conditioning and haplo-identical donor regimens for HSCT, post-transplant strategies for preventing and treating relapse, and emerging novel therapeutic options.
Source: Leukemia Research Reports - Category: Hematology Source Type: research